Post Reply
21-40 of 1738
If TG UG and Medtecs up by 30-50% surely this one can up 10% right?
This counter dont waste time la. Drop like no tmrw.
Is this medical stock Covid related ? I remember it was being played to 70 over cents during the last Covid period. Will it be pushed up this time round.
0.225 taking..
Seems like investor kena killed instead of shortist
Shortists may be killed due to strong dividend announcement.
Contratrader ( Date: 24-Sep-2021 17:38) Posted:
|
Vicplas International posts 2.1 times earnings growth for FY21, declares DPS of 0.45 cents
Vicplas International has posted earnings of $10.4 million for FY2021 ended July, up 112.5% from $4.9 million the previous year.This translates to earnings per share of 2 cents on a fully diluted basis, up from 0.98 cents the previous year.
Revenue for the period increased by 28.2% to $113.9 million in FY2021 from $88.8 million in FY2020, driven by higher revenue from both medical devices and pipes and pipe fittings segments.
The higher revenue was driven by both its medical devices as well as its pipes and pipe fittings segment. The medical devices segment saw revenue increase 30.6% to $80.2 million in FY2021, due to increased orders from its customers, while revenue from the pipes and pipe fittings segment increased 22.9% to $33.8 million, due to the gradual recovery in the construction industry from the disruptions caused by the Covid-19 pandemic.
Other income increased by 32.4% in FY2021 to $6.9 million due to more tools built for customers in the medical devices segment and foreign exchange gain, despite a $0.9 million reduction in Covid-19 related government subsidies in FY2021 as compared to FY2020.
The group recorded a profit before tax of $12.3 million and a profit after tax of 10.4 million for FY2021, up 71.6% y-o-y.
Vicplas is recommending a final dividend of 0.45 cents per ordinary share for FY2021, 20% higher than the dividend of 0.375 cents per share for FY2020.
In view of opportunities to keep growing the Group' s medical devices segment, Vicplas sstates more capital has been retained in the business to support such growth in the long term interest of shareholders. In addition, the group is mindful of the uncertainties in the macro environment as well as the Group' s working capital, cashflow and capital expenditure requirements.
" In FY2021, Vicplas achieved its best results ever with the medical devices segment' s positive growth trajectory and the pipes and pipe fittings segment recovering in tandem with the construction industry. With a challenging operating environment due to the ongoing Covid-19 pandemic and uncertainties in the wider macro environment, the Group remains cautiously optimistic for the year ahead," says Cheng Liang, Vicplas' CEO.
Should follow the fate of Biolidics...
Monday short! Follow the BB.
I also think this counter GG liao.... took the recent bounce to clear off my holdings and cut loss.... too painful to see it range bound at the miserable low 20s and 19s..... have a great weekend folks!
short it to sub 20
think difficult to sell at 0.245
TodaySgCny ( Date: 24-Sep-2021 11:41) Posted:
|
Never trusted this counter
Holding Vp at 0.22 and 0.24 average 0.23.Should have sold yesterday.BB accumulating,should eat up.Try later after lunch 95k sell holding at 0.245.
Bye bye vicplas. 4th time cry wolf..
shorted and covered liow...
sell on news
spursfan ( Date: 24-Sep-2021 08:24) Posted:
|
MEDIA RELEASE
Vicplas International&rsquo s FY2021 net profit rose 112.5% to S$10.4 million with medical devices segment driving growth
Medical devices segment continues its positive growth trajectory and achieves record results
Pipes and pipe fittings segment&rsquo s performance improves as Singapore construction sector recovers
Increase dividend by 20%
SINGAPORE, 24 September 2021 &ndash SGX Mainboard-listed Vicplas International Ltd (&ldquo Vicplas&rdquo , &ldquo 威 百 亿 国 际 有 限 公 司 &rdquo or the &ldquo Company&rdquo , or collectively with its subsidiaries, the &ldquo Group&rdquo ), is pleased to announce that it has achieved a profit after tax of S$10.4 million for the financial year ended 31 July 2021 (&ldquo FY2021&rdquo ), an increase of 112.5% from S$4.9 million for the financial year ended 31 July 2020 (&ldquo FY2020&rdquo ).
https://links.sgx.com/1.0.0/corporate-announcements/2ZJU2N5OZ603PH2E/684466_2021.09.24%20Vicplas%20FY2021%20Results%20Media%20Release.pdf
Vicplas International&rsquo s FY2021 net profit rose 112.5% to S$10.4 million with medical devices segment driving growth
Medical devices segment continues its positive growth trajectory and achieves record results
Pipes and pipe fittings segment&rsquo s performance improves as Singapore construction sector recovers
Increase dividend by 20%
SINGAPORE, 24 September 2021 &ndash SGX Mainboard-listed Vicplas International Ltd (&ldquo Vicplas&rdquo , &ldquo 威 百 亿 国 际 有 限 公 司 &rdquo or the &ldquo Company&rdquo , or collectively with its subsidiaries, the &ldquo Group&rdquo ), is pleased to announce that it has achieved a profit after tax of S$10.4 million for the financial year ended 31 July 2021 (&ldquo FY2021&rdquo ), an increase of 112.5% from S$4.9 million for the financial year ended 31 July 2020 (&ldquo FY2020&rdquo ).
https://links.sgx.com/1.0.0/corporate-announcements/2ZJU2N5OZ603PH2E/684466_2021.09.24%20Vicplas%20FY2021%20Results%20Media%20Release.pdf
Dividends increased nice
Think this company is supplying the ART test kit
Sibehboeng ( Date: 23-Sep-2021 17:42) Posted:
|
